
|Videos|July 28, 2022
Study explores patient-reported outcomes for UGN-102 in NMIBC
Author(s)Urology Times staff
“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.
Advertisement
In this video, Angela M. Stover, PhD, discusses the rationale and notable findings from the Journal of Urology study, “Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer,” for which she served as a study author. Stover is an assistant professor of health policy and management at the University of North Carolina, Chapel Hill.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5










